Aim: Despite the availability of effective long-term therapies for gout, poor adherence to medication poses a significant barrier to effective treatment. This pilot study assesses the feasibility and acceptability of a nurse-led interprofessional medication adherence program for people with gout at Liverpool Hospital (Australia).
Method: Patients who meet the inclusion criteria are invited to participate in the pilot study; ≥18 years with gout; English or Arabic speaking; serum urate >0.36 mmol/L; previous hospital presentation with gout within the last 12 months; prescribed allopurinol.
A nurse provides monthly medication support, education, motivational interviewing and electronic adherence monitoring and feedback for 3 months. At the conclusion of the study, semi-structured interviews with patients and health professionals are conducted and thematically analysed to describe their experiences and satisfaction with the program. Interviews with executive hospital decision-makers were also conducted to evaluate program acceptability. Study participation (recruitment/attendance/attrition), adverse events, and intervention costs will also be evaluated.
Results: The IIMAP-Gout feasibility study recruited 10 patients from April to July 2023. This included 9 males and 1 female, with a mean age of 50. Participants predominantly identified as Pacific Islander (5), followed by Asian (4) and Caucasian (1). In total 30 eligible participants were contacted face-to-face or over the phone (average recruitment rate of 33%). Semi-structured interviews have been conducted with 2 patients, a rheumatologist and a clinical nurse specialist. Difficulties encountered throughout recruitment included patients not attending scheduled appointments, patients declining participation due to excessive time commitment and poor resource availability.
Discussion and Conclusion: Initial poor rates of recruitment to the service require further investigation. The pilot study will inform the feasibility and acceptability of the nurse-led interdisciplinary medication adherence program, allowing for further adaptions for a model of care that addresses barriers to medication adherence and improves outcomes in people with gout.